This 10mg blend combines CJC-1295 (Mod GRF 1-29) 5mg and GHRP-6 5mg in a single vial, synthesized and lyophilized in the USA.
Each vial of CJC-1295 (Mod GRF 1-29) & GHRP-6 Blend (10mg) contains a pre-weighed ratio of CJC-1295 5mg, GHRP-6 5mg in a single lyophilized cake, simplifying multi-peptide research protocols.
Researchers pair CJC-1295 (Mod GRF 1-29) & GHRP-6 Blend (10mg) with pulse-profile analysis to characterize its release dynamics under standardized conditions.
Comparative studies of CJC-1295 (Mod GRF 1-29) & GHRP-6 Blend (10mg) often benchmark its potency against reference peptides in the same family.
CJC-1295 (Mod GRF 1-29) & GHRP-6 Blend (10mg) appears in dose-escalation designs that track tolerance and response stability across experimental groups.
Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.
Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.
Research & Literature
The following peer-reviewed studies and reference documents are commonly consulted by researchers working with CJC-1295 (Mod GRF 1-29) & GHRP-6 Blend (10mg). Summaries are provided for orientation only and reflect the cited sources.
Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults[1] — This study assessed the growth hormone and IGF-I responses to a single injection of the long-acting GHRH analog CJC-1295 in healthy adults. The authors examined the duration and magnitude of hormonal elevation following administration. The findings indicated that CJC-1295 produces prolonged stimulation of the GH-IGF-I axis, providing reference for the GHRH analog family to which Mod GRF 1-29 belongs. (The Journal of Clinical Endocrinology & Metabolism 2006)
Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog[2] — This study examined whether continuous stimulation by the long-acting GHRH analog CJC-1295 alters the pulsatile pattern of growth hormone secretion. The authors reported that GH pulsatility was preserved while trough GH and IGF-I levels were raised. The findings suggested that GHRH-class peptides amplify GH output without disrupting its physiological pulsatile rhythm. (The Journal of Clinical Endocrinology & Metabolism 2006)
Development of growth hormone secretagogues[3] — This review summarized the discovery and development of growth hormone secretagogues, including GHRP-6 and other ghrelin receptor ligands. The author traced how these compounds were identified and characterized as stimulators of endogenous GH release. The review provided context for the research use of GHRP-class peptides such as GHRP-6. (Endocrine Reviews 2005)
Growth hormone-releasing peptides[4] — This review described the pharmacology and GH-releasing activity of synthetic growth hormone-releasing peptides such as GHRP-6. The authors discussed the mechanisms through which these peptides stimulate pituitary GH secretion. The review supported the classification of GHRP-6 as a potent member of the GHRP family. (European Journal of Endocrinology 1997)
References
Teichman SL, et al.. "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults." The Journal of Clinical Endocrinology & Metabolism. 2006. academic.oup.com/jcem/article-pdf/91/3/799/10779632/jcem0799.p…
Ionescu M, Frohman LA. "Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog." The Journal of Clinical Endocrinology & Metabolism. 2006. academic.oup.com/jcem/article-pdf/91/12/4792/9059878/jcem4792.…
Ghigo E, Arvat E, Muccioli G, Camanni F. "Growth hormone-releasing peptides." European Journal of Endocrinology. 1997. pubmed.ncbi.nlm.nih.gov/9186261/
All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.
Which research areas commonly use CJC-1295 (Mod GRF 1-29) & GHRP-6 Blend (10mg)?
CJC-1295 (Mod GRF 1-29) & GHRP-6 Blend (10mg) is most often referenced in studies related to growth-hormone axis and secretagogue signaling. Typical laboratory protocols combine dose-response assays with purity verification before experimental application.
What is the purity of CJC-1295 (Mod GRF 1-29) & GHRP-6 Blend (10mg)?
All batches are purified by reversed-phase HPLC and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request.
How is CJC-1295 (Mod GRF 1-29) & GHRP-6 Blend (10mg) packaged?
Each vial contains lyophilized peptide at the labeled quantity. Wholesale orders are packed in boxes of ten vials at a single per-vial price.
How should CJC-1295 (Mod GRF 1-29) & GHRP-6 Blend (10mg) be stored?
Store lyophilized vials at -20°C, protected from light and moisture. Reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles.
Is CJC-1295 (Mod GRF 1-29) & GHRP-6 Blend (10mg) for human or veterinary use?
No. All products are supplied for in-vitro laboratory research use only and are not for human or veterinary use.
Batch Certificates of Analysis
Every production batch of this product is analyzed by HPLC (purity) and mass spectrometry (identity). Certificates accompany each order and are available on request for any batch.
HPLC-UV purity report with chromatogram
MS identity report with molecular weight confirmation
